HCM Q2 2020 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena

HCMHUTCHMED (China) Limited

$3B

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$55M+10.3% YoY

Gross Profit

$13M23.4% margin

Operating Income

-$46M-82.7% margin

Net Income

-$34M-60.8% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+7.0%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$29M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$526M

Total Liabilities

$159M

Stockholders' Equity

$342M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$50M	+10.3%
Gross Profit	$13M	$12M	+4.2%
Operating Income	-$46M	-$36M	-27.0%
Net Income	-$34M	-$25M	-31.7%

Revenue Segments

Product

$95M91%

Collaboration Research And Development

$8M7%

Other Collaboration Royalties Revenue

$2M2%

Research And Development Services

$240,0000%